Effect of envafolimab combined with apatinib in second-line treatment of recurrent/metastatic programmed cell death 1 ligand 1 positive advanced cervical cancer patients
Objective To investigate the effect of envafolimab combined with apatinib in second-line treatment of re-current/metastatic programmed cell death 1 ligand 1(PD-L1)positive advanced cervical cancer patients.Method A total of 70 patients with recurrent/metastatic PD-L1 positive advanced cervical cancer were divided into observation group(n=39,envafolimab combined with apatinib second-line treatment)and control group(n=31,apatinib second-line treatment)according to different treatment methods.The tumor markers[vascular endothelial growth factor(VEGF),squamous cell carcinoma antigen(SCCA)]levels,immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+),clinical efficacy and inci-dence of adverse reactions were compared between the two groups.Result After treatment,the VEGF,SCCA and CD8+levels in two groups were lower than those before treatment,the CD3+,CD4+levels and CD4+/CD8+were higher than those before treatment,the VEGF,SCCA and CD8+levels in observation group were lower than those in control group,the CD3+,CD4+levels and CD4+/CD8+were higher than those in control group,and the differences were statistically sig-nificant(P<0.05).The total effective rate in observation group was higher than that in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions be-tween the two groups(P>0.05).Conclusion Envafolimab combined with apatinib in the second-line treatment of pa-tients with recurrent/metastatic PD-L1 positive advanced cervical cancer can reduce the tumor marker levels and improve the immune function of patients,with good clinical efficacy and high safety.
envafolimabapatinibcervical cancerprogrammed cell death 1 ligand 1second-line treatment
NETL
NSTL
万方数据
